Clinical trial · no report yet · Phase not applicable

NUTRIVENTION-3

A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)

NCT05640843 ↗
Recruiting
Memorial Sloan Kettering Cancer Center
Standard

We haven't built an HCP commentary report on NUTRIVENTION-3 (Monoclonal Gammopathy of Undetermined Significance) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on NUTRIVENTION-3 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Channel	Indexed
YouTube	15
X threads	2
Bluesky threads	2

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: A Randomized Placebo Controlled Study of a Plant-Based Dietary Versus Supplement Versus Placebo Intervention in Patients With Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) - The Nutrition Prevention (NUTRIVENTION-3) Study
Phase: Phase not applicable
Status: Recruiting
Conditions: Monoclonal Gammopathy of Undetermined Significance; Smoldering Multiple Myeloma
Interventions: Whole Foods Plant-based Diet; Algae Omega 3 + Curcumin; Placebo supplements
Arms: Daily Harvest weekly · Experimental
Supplements · Experimental
Placebo · Placebo comparator
Enrollment: 180 (estimated)
Primary outcomes: Stool microbiome diversity at 12 weeks
Sponsor: Memorial Sloan Kettering Cancer Center with Paula and Rodger Riney Foundation, Plantable, M and M labs, VeggieDoctor, Sabinsa pharmaceuticals, Daily Harvest
Start: Nov 29, 2022
Primary completion: Nov 2026 (estimated)
Results posted: No
Registry record: NCT05640843 · updated Apr 16, 2026